Prostatype Genomics AB (PROGEN) - Total Assets
Based on the latest financial reports, Prostatype Genomics AB (PROGEN) holds total assets worth Skr43.84 Million SEK (≈ $4.72 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Prostatype Genomics AB (PROGEN) net assets for net asset value and shareholders' equity analysis.
Prostatype Genomics AB - Total Assets Trend (2015–2024)
This chart illustrates how Prostatype Genomics AB's total assets have evolved over time, based on quarterly financial data.
Prostatype Genomics AB - Asset Composition Analysis
Current Asset Composition (December 2024)
Prostatype Genomics AB's total assets of Skr43.84 Million consist of 28.2% current assets and 71.8% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 22.4% |
| Accounts Receivable | Skr1.78 Million | 4.3% |
| Inventory | Skr95.00K | 0.2% |
| Property, Plant & Equipment | Skr0.00 | 0.0% |
| Intangible Assets | Skr29.27 Million | 69.7% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2015–2024)
This chart illustrates how Prostatype Genomics AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Prostatype Genomics AB market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Prostatype Genomics AB's current assets represent 28.2% of total assets in 2024, a decrease from 82.9% in 2015.
- Cash Position: Cash and equivalents constituted 22.4% of total assets in 2024, down from 61.6% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 69.0% of total assets, an increase from 8.0% in 2015.
- Asset Diversification: The largest asset category is intangible assets at 69.7% of total assets.
Prostatype Genomics AB Competitors by Total Assets
Key competitors of Prostatype Genomics AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$17.03 Billion |
|
Eurofins-Cerep SA
PA:ALECR
|
France | €84.58 Million |
|
Inoviq Ltd
AU:IIQ
|
Australia | AU$24.52 Million |
|
Bcal Diagnostics Ltd
AU:BDX
|
Australia | AU$7.17 Million |
|
Imagion Biosystems Ltd
AU:IBX
|
Australia | AU$932.48K |
|
Integral Diagnostics Ltd
AU:IDX
|
Australia | AU$1.43 Billion |
|
Australian Clinical Labs Ltd
AU:ACL
|
Australia | AU$562.50 Million |
|
Monash Ivf Group Ltd
AU:MVF
|
Australia | AU$510.21 Million |
Prostatype Genomics AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.95 | 0.17 | 0.40 |
| Quick Ratio | 1.93 | 0.16 | 0.37 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr7.01 Million | Skr-15.81 Million | Skr-9.07 Million |
Prostatype Genomics AB - Advanced Valuation Insights
This section examines the relationship between Prostatype Genomics AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.89 |
| Latest Market Cap to Assets Ratio | 0.12 |
| Asset Growth Rate (YoY) | -14.7% |
| Total Assets | Skr41.97 Million |
| Market Capitalization | $4.83 Million USD |
Valuation Analysis
Below Book Valuation: The market values Prostatype Genomics AB's assets below their book value (0.12x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Prostatype Genomics AB's assets decreased by 14.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Prostatype Genomics AB (2015–2024)
The table below shows the annual total assets of Prostatype Genomics AB from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Skr41.97 Million ≈ $4.52 Million |
-14.73% |
| 2023-12-31 | Skr49.22 Million ≈ $5.30 Million |
+59.04% |
| 2022-12-31 | Skr30.95 Million ≈ $3.33 Million |
-23.02% |
| 2021-12-31 | Skr40.20 Million ≈ $4.33 Million |
+19.43% |
| 2020-12-31 | Skr33.66 Million ≈ $3.62 Million |
+91.55% |
| 2018-12-31 | Skr17.57 Million ≈ $1.89 Million |
-10.84% |
| 2017-12-31 | Skr19.71 Million ≈ $2.12 Million |
-0.01% |
| 2016-12-31 | Skr19.71 Million ≈ $2.12 Million |
+375.57% |
| 2015-12-31 | Skr4.15 Million ≈ $446.11K |
-- |
About Prostatype Genomics AB
Prostatype Genomics AB (publ) manufactures, markets, and sells prognostic gene tests. The company offers Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, gleason score, and tumor stage, as well as calculates the P-score. Its test is based on database containing prostate cancer patients; and provides decision support for patients and doct… Read more